David W. Denning MBBS, FRCP, FRCPath, DCH, FMedSci

David Denning is a research clinician with expertise in fungal diseases, now retired from clinical practice. He initiated and manages The Aspergillus Website (1998 -) and was the Founding Director of the National Aspergillosis Centre (2010-2020). He founded 2 biotech companies; F2G Ltd, an antifungal drug discovery and development company (olorofim in Phase 2 clinical study), and Myconostica Ltd (sold to Novacyt) which developed and commercialized real-time molecular tests for fungal infections. His research with colleagues at the Manchester Fungal Infection Group includes basic research (genomics, pathogenesis, and mechanism of antifungal drug resistance) and he maintains many other active research interests in diagnostics, new antifungal agents, and the epidemiology of fungal disease globally.

Earlier in his career, Dr. Denning developed a blood assay for aflatoxin, documented transplacental transfer of aflatoxin; developed a discriminatory molecular typing scheme for A. fumigatus, described azole resistance in Aspergilli, and led the A. fumigatus genome sequencing project (published in Nature in 2005). He was integral to the successful completion of the randomized study comparing voriconazole with amphotericin B, published in 2002, and led the randomized double-blind placebo-controlled study of itraconazole for severe asthma with fungal sensitization, published in 2009. He has published more than 650 papers, books, and book chapters, including an undergraduate textbook of Medicine. His work has been cited over 75,000 times.